AMRN — Amarin Corporation PLC
NASDAQ · Healthcare · Drug Manufacturers - General
$14.10
+$0.25 (+1.84%)
Amarin Corporation PLC (AMRN) is a drug manufacturers - general company listed on NASDAQ. It is led by Aaron D. Berg, based in One Central Plaza, Dublin, Ireland, D02 K7K5, with about 80 employees. Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Latest reported AMRN revenue for 2025-09-30 was $49.7M. Net income was -$37.6M. Revenue was down 31.7% from 2025-06-30 to 2025-09-30. AMRN currently screens at market cap $292.1M.
Use this AMRN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AMRN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AMRN SEC filings page. Lician reads the product cache first so this HTML stays unique to Amarin Corporation PLC even when a live quote feed is slow.
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
AMRN Key Statistics
Market Cap
$292.10M
Volume
90,633
Previous Close
$14.15
Day Range
$14.17 – $15.24
EPS
-$0.20
Revenue
$228.61M
Net Income
-$82.18M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-25.5%
Profit Margin
-35.9%
Employees
80
AMRN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $228.61M | $306.91M | $369.19M | $583.19M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$82.18M | -$59.11M | -$105.80M | $7.73M |
| EPS (Diluted) | -$0.20 | -$0.15 | -$0.26 | $0.02 |
Total Assets
$685.35M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$121.04M
Operating Cash Flow
-$31.02M
Free Cash Flow
$0.00
Amarin Corporation PLC Company Information
- CEO, President & Director
- Aaron D. Berg
- Headquarters
- One Central Plaza, Dublin, Ireland, D02 K7K5
- Website
- www.amarincorp.com
- Phone
- 353 0 166 99020
- IPO / Founded
- 1993-04-01
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General